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Toward a European definition for a
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Elfi De Weerdt*, Steven Simoens, Minne Casteels and Isabelle Huys
Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven,
Leuven, Belgium
Background: Drug shortages are currently on the rise. In-depth investigation of
the problem is necessary, however, a variety of definitions for ‘drug shortages’ are
formulated in legislations, by different organizations, authorities, and other initiatives.
For international comparison, the underlying definition for drug shortages is important
to allow appropriate interpretation of national databases and the results of scientific
studies. The objective is to identify the different elements which should be considered
in a uniform definition for drug shortages in the European Union (EU) and to detect the
different conditions for reporting drug shortages.
Materials and Methods: Definitions of drug shortages were searched in the scientific
databases as well as in the gray literature. Similar topics were identified and
organizations were contacted to formulate the reasoning underlying the definitions.
Results: Over 20 different definitions for drug shortages were identified. A distinction
is made between general definitions of drug shortages and definitions used for the
reporting of drug shortages. Differences and similarities are observed in the elements
within the definitions, e.g., when does a supply problem become a drug shortage,
permanent and/or temporally shortages, the typology and time frame of a drug shortage.
The moment a supply problem is considered as a shortage, can be defined at four
levels: (i) demand side, (ii) supply side, (iii) delivery of a drug, and (iv) availability of a
drug. Permanent discontinuations of drugs are not always covered in definitions for
drug shortages. Some definitions only consider those drugs used for the treatment of
serious diseases or drugs for which no alternative is available. Different time frames were
observed, varying between 1 day and 20 days.
Conclusion: Obtaining a uniform definition for drug shortages is important as well as
identifying which conditions are preferable to report drug shortages in order to facilitate
international benchmarking. This paper can be used as a guidance to point out all the
different elements which should be considered to formulate a uniform definition to be
applied in the EU.
Keywords: drug shortages, supply problems, definition and concepts, semantics, qualitative research, literature
review
Abbreviations: AEMPS, Spanish Agency of Medicines and Medical Devices (Spain); AIFA, Italian Medicines Agency
(Italy); ANSM, French National Agency for Medicines and Health Products Safety (France); ASHP, American Society
of Hospital Pharmacies (US); BfArM, Federal Institute for Drugs and Medical Devices (Germany); EAHC, Executive
Agency for Health and Consumers; EFPIA, European Federation of Pharmaceutical Industries and Associations; EMA,
European Medicines Agency; FAMHP, Federal Agency of Medicines and Health Products (Belgium); Farmanco, Royal
Dutch Pharmacists Association Farmanco (the Netherlands); FDA, Food and Drug Association (US); FIP, International
Pharmaceutical Federation; ISPE, International Society of Pharmaceutical Engineering.
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INTRODUCTION
Recently, drug shortages have become a common problem in
European Union (EU) Member States (European Association
of Hospital Pharmacists, 2014). During the past decades, the
awareness for drug shortages has been grown due to the
observation of an increased number of drug shortages. Diﬀerent
stakeholders are engaged in the problem. In the ﬁrst place,
hospital as well as community pharmacies are aﬀected by drug
shortages. Patients are also troubled by this problem as well
as medical doctors and nurses. They might be less familiar
with the alternative treatment in case of a drug shortage,
which can lead to medication errors (Pharmaceutical Group
of the European Union, 2012; Yurukoglu, 2012; European
Association of Hospital Pharmacists, 2014; Heiskanen et al.,
2014). Diﬀerent umbrella organizations of the pharmaceutical
industry published papers on drug shortages, some of them
including guidelines on how to prevent and reduce risks for
shortages. These actions suggest that drug shortages are also
to the detriment of the pharmaceutical companies, due to the
reputational damage it may provoke (European Association of
Pharmaceutical Full-line Wholesalers (GIRP), 2013; European
Federation of Pharmaceutical Industries and Associations, 2013;
ISPE, 2014). National competent authorities are also burdened
with the problem of drug shortages. Due to the EU Directive
2001/83/EC, national competent authorities should control the
continue supply of drugs and should be warned by the suppliers
of every cessation of pharmaceutical products whether this is
temporally or permanently (The European Parliament and the
Council of the European Union, 2011; De Weerdt et al., 2015).
Until recently, studies on drug shortages were mainly found in
US literature (Kaakeh et al., 2011; Ventola, 2011; Kweder andDill,
2013; Woodcock and Wosinska, 2013; Fox et al., 2014). These
studies investigated the scope, the causes and impact of drug
shortages in the US. In recent years, more research concerning
drug shortages in Europe has been published, trying to gage
the scope and causes of drug shortages (Costelloe et al., 2014;
Heiskanen et al., 2014; Pauwels et al., 2014, 2015). However, the
results of these studies are hard to compare as diﬀerent deﬁnitions
of drug shortages have been used.
Should a drug supply problem always be considered as a drug
shortage or should it only be considered when patients have no
longer access to a particular medicine? Are drug shortages taken
into account when drugs cannot be delivered for only one day
and thus should a time frame be considered in the deﬁnition of
drug shortages? When manufacturers retract a product from the
market, should it be considered as a drug shortage?
The objective of this paper is to identify the essential elements
which are crucial in a deﬁnition for drug shortages and to identify
which conditions are preferable to be considered when reporting
drug shortages in databases. In order to achieve these aims, it was
important to understand the reasons why certain organizations
decided to develop their own drug shortage deﬁnition.
A uniform deﬁnition at EU level together with its reporting
conditions will facilitate the problem of drug shortages
at diﬀerent levels. Firstly, international comparison will be
facilitated, especially if the national databases of the reported
drug shortages are publicly accessible, e.g., national competent
authorities can easily control whether a drug shortage is an
international or national problem. This information can also help
them to ﬁnd potential solutions. Secondly, the scope of drug
shortages can be objectively estimated. Understanding the scale
of the problem will help to take appropriate action against drug
shortages by industry as well as national authorities. And thirdly,
a uniform deﬁnition will also facilitate the communication
between diﬀerent stakeholders.
MATERIALS AND METHODS
Because the nature of the study, it was not required to seek
approval from a research ethics committee. Data were analyzed
anonymously.
Data were collected in the scientiﬁc literature as well as
in the gray literature between October the 6th 2014 and
April the 31th 2015. Scientiﬁc articles were identiﬁed in the
following databases: MEDLINE, Embase, and Web of Science.
The search strategy was developed incorporating synonyms
for “drug shortages” combined with “deﬁn*”. By using an
asterisk every word starting with “deﬁn” was included. Individual
search terms and MeSH search terms were used alone and
in combinations. Studies published in English, French, Dutch,
and German were included in the paper. Additionally, the
bibliography of the retrieved papers was checked for other
relevant articles or studies. Gray literature, which are websites
and documents of diﬀerent stakeholders, was also searched for
deﬁnitions of drug shortages. Some examples of possible sources
which were searched for deﬁnitions are: legislations (e.g., Belgian
law, EU Directives, etc.); governmental organizations (e.g.,
AIFA etc), professional organizations [FIP; European Hospital
Pharmacists Associations (EAHP), etc.]; patient organizations
(e.g., European Public Health Alliance, etc.). The same language
criteria as described above were applied to gray literature
documents.
Deﬁnitions were analyzed according to their literary
diﬀerences and similarities. Main topics as: “the level of supply,”
“permanent or temporally discontinuation,” “time limit,” and
“typology” were identiﬁed. These topics were investigated and
observed diﬀerences and similarities were subdivided.
To identify the reasoning behind the wordings within the
identiﬁed general deﬁnitions, the organizations and national
authorities that formulated those deﬁnitions were contacted.
Three main questions were asked: (i) “when should supply
problems be considered as drug shortages? Should drug shortages
include supply problems when patients are not aﬀected (meaning:
when patients have to switch to another (generic) medicine, they
are aﬀected)?”; (ii) “do you believe a time frame is important
in the deﬁnition of a drug shortage? Please reason why”; and
(iii) “Does the deﬁnition also include drugs which have been
permanently discontinued? Please explain”. These questions were
sent via email to diﬀerent organizations (seven national and
four international). Answers were obtained from four national
organizations and two international organizations. Appropriate
quotes were selected from the answers and were translated from
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Dutch to English. Deleted parts of the quotes are indicated by
“. . .”. The coding [R1, R2, etc.] identiﬁes the respondent.
RESULTS
From the literature review 26 diﬀerent deﬁnitions for drug
shortages are identiﬁed (Wet Betreﬀende de Verplichte
Verzekering Voor Geneeskundige Verzorging En Uitkeringen
Gecoördineerd Op 14 Juli, 1994; Fox et al., 2009; Food and
Drug Administration, 2011a; Dragic, 2012; Executive Agency
for Health and Consumers, 2012; Instituut voor Verantwoord
Medicijngebruik, 2012; Charnay-Sonnek et al., 2013; European
Federation of Pharmaceutical Industries and Associations, 2013;
European Medicines Agency, 2013; Fédération Internationale
Pharmaceutique, 2013; ISPE, 2013; ANSM, 2014; Costelloe et al.,
2014; Government of Canada - Health Canada, 2014; Federaal
Agentschap voor Geneesmiddelen en Gezondheidsproducten,
2014; Heiskanen et al., 2014; Koninklijke Nederlandse
Maatschappij ter bevordering der Pharmacie, 2014; The Italien
Medicines Agency, 2014; Agencia Española de Medicamentos Y
Productos Sanitarios - AEMPS, 2015; Australian Government -
Department of Health - Therapeutic Goods Administration
[TGA], 2015; BfArM - Lieferengpässe, 2015; Canadian Drug
Shortage Database, 2015; Décret N◦ 2012-1096 Du 28 Septembre
2012 Relatif À L’approvisionnement En Médicaments À Usage
Humain, 2015; Pauwels et al., 2015). Diﬀerent sources are
acknowledged, including: national laws, governmental and
professional organizations, and scientiﬁc articles. All deﬁnitions
found are unique, with the exception that most scientiﬁc articles
refer to already existing deﬁnitions of the ASHP and/or the FDA
(Balkhi et al., 2013; Becker et al., 2013; Wiggins et al., 2014).
The deﬁnitions will be divided into three categories: (i) general
deﬁnitions for drug or medicine shortages, (ii) deﬁnitions
specifying the conditions to report drug shortages, and (iii)
deﬁnitions found in articles. It occurs that in some countries
more than one deﬁnition is exploited: e.g., a deﬁnition for a
drug shortage (national law) and a deﬁnition for the purpose
of reporting a drug shortage (federal agency) (Wet Betreﬀende
de Verplichte Verzekering Voor Geneeskundige Verzorging En
Uitkeringen Gecoördineerd Op 14 Juli, 1994; Fox et al., 2009;
Food and Drug Administration, 2011b; Federaal Agentschap
voor Geneesmiddelen en Gezondheidsproducten, 2014).
The four deﬁnitions of drug shortages found in scientiﬁc
articles will not be discussed in further detail, because the aim of
these deﬁnitions is to clarify which shortages are covered by the
scope of such paper.
In total 14 general deﬁnitions for drug shortages are found,
including two references of national laws (Belgium and France),
ﬁve of governmental organizations, six papers of professional
organizations and a deﬁnition of the EMA which was formulated
in 2014, however, at the current time, that deﬁnition is
removed from the EMA website (Wet Betreﬀende de Verplichte
Verzekering Voor Geneeskundige Verzorging En Uitkeringen
Gecoördineerd Op 14 Juli, 1994; Fox et al., 2009; Food and
Drug Administration, 2011b; Executive Agency for Health and
Consumers, 2012; Instituut voor Verantwoord Medicijngebruik,
2012; Charnay-Sonnek et al., 2013; European Federation of
Pharmaceutical Industries and Associations, 2013; Fédération
Internationale Pharmaceutique, 2013; ISPE, 2013; Government
of Canada - Health Canada, 2014; The Italien Medicines
Agency, 2014; Australian Government - Department of Health -
Therapeutic Goods Administration [TGA], 2015; Décret N◦
2012-1096 Du 28 Septembre 2012 Relatif À L’approvisionnement
En Médicaments À Usage Humain, 2015). An overview of these
deﬁnitions can be found in Table 1.
Seven deﬁnitions of drug shortages for reporting purposes
were found on websites of (inter)national authorities; one more
was obtained by contacting the Farmanco, the Dutch reporting
database. Reporting websites are mostly nationally regulated,
except for the database of EMA (European Medicines Agency,
2013; ANSM, 2014; Federaal Agentschap voor Geneesmiddelen
en Gezondheidsproducten, 2014; Koninklijke Nederlandse
Maatschappij ter bevordering der Pharmacie, 2014; Agencia
Española de Medicamentos Y Productos Sanitarios - AEMPS,
2015; Australian Government - Department of Health -
Therapeutic Goods Administration [TGA], 2015; BfArM -
Lieferengpässe, 2015; Canadian Drug Shortage Database, 2015).
Table 2 displays an overview of these eight deﬁnitions.
Remarkable diﬀerences between the deﬁnitions, such as “when
do supply problems become drug shortages”; “permanent or
temporally discontinuation”; “typology” and “time frame”, will be
discussed in further detail in the next subsections.
When do Supply Problems become Drug
Shortages?
Not every supply problem immediately causes a drug shortage.
In the deﬁnitions, diverse wordings are found to describe when
supply problems become drug shortages. Shortages can be
expressed in four diﬀerent ways, speciﬁcally according to (i)
the demand side (e.g., when the supply of a drug is inadequate
to meet the current or projected demand), (ii) the supply
side (e.g., interruption of supply), (iii) the delivery of a drug
(e.g., undeliverable), and (iv) the availability of drugs (e.g., the
availability of drugs to patients). Additionally drug shortages
can occur at two diﬀerent levels, namely (a) at pharmacies or
wholesalers and (b) at consumers’ level. The diﬀerent expressions
will be discussed in the next paragraphs.
Demand Side
With respect to the demand side, the formulation: “when the
supply of a drug is inadequate to meet the current or projected
demand” is found in ﬁve general deﬁnitions, including the
deﬁnitions of the FDA, International Society Pharmaceutical
Engineering (ISPE), Australian Health Department, Health
Canada as well as the deﬁnition found in the common position
paper by Charnay-Sonnek et al. (2013) (see Table 1) and one
deﬁnition for reporting purposes, namely of the Canadian Drug
Shortages Database (see Table 2; Food and Drug Administration,
2011b; Charnay-Sonnek et al., 2013; ISPE, 2013; Government
of Canada - Health Canada, 2014; Australian Government -
Department of Health - Therapeutic Goods Administration
[TGA], 2015; Canadian Drug Shortage Database, 2015). These
wordings indirectly suggest that supply problems at pharmacy
Frontiers in Pharmacology | www.frontiersin.org 3 October 2015 | Volume 6 | Article 253
De Weerdt et al. How should drug shortages be defined?
TABLE 1 | Overview of the general definitions of drug shortages.
Source Definition
Legislations
Belgian law (Wet Betreffende de Verplichte Verzekering Voor Geneeskundige
Verzorging En Uitkeringen Gecoördineerd Op 14 Juli, 1994)
On compulsory insurances for medical care coordinated on 14th July
1994 – art. 72 bis
A drug is unavailable when enterprises which are responsible for the marketing of
the drug are unable to deliver that drug for an uninterrupted period of four days to
the community pharmacies, hospital pharmacies, or wholesalers in Belgium.
French law (Décret N◦ 2012-1096 Du 28 Septembre 2012 Relatif À
L’approvisionnement En Médicaments À Usage Humain, 2015)
Decree n◦ 2012-1096 the 28th of September 2012 on the supply of medicines for
human use
A supply disruption is the inability for a dispensary pharmacy or internal use
pharmacy dispensing a drug to a patient within 72 h or within a shorter time
depending on the compatibility problems with the continued treatment of the
patient.
Governmental organizations
Dutch Institute for Rational Use of Medicine (Instituut voor Verantwoord
Medicijngebruik, 2012)
The (temporally) not or inadequate supply of a registered pharmaceutical.
AIFA (The Italien Medicines Agency, 2014) When a medicinal product is not available or commercially unavailable all over the
country and the market authorization holder does not assure appropriate and
continued supply to meet the patients’ needs.
EMA When the delivery of a medicine cannot comply to the needs of the patients,
whether this is local, national, or international.
FDA (Food and Drug Administration, 2011b) A situation in which the total supply of all clinical interchangeable versions of a
FDA-regulated drug is inadequate to meet the current or projected demand at the
patient level.
Health Canada (Government of Canada - Health Canada, 2014) A drug shortage is a situation when a manufacturer or importer of a drug cannot
meet actual or projected demand. Drug shortages can include temporary
disruptions or permanent discontinuances in the production and supply of a drug.
Australian Ministry of Health (Australian Government - Department of
Health - Therapeutic Goods Administration [TGA], 2015
A medicine shortage occurs when the supply of a medicine is not likely to meet the
normal or projected consumer demand for the medicine within Australia for a period
of time.
Professional organizations
ISPE (ISPE, 2013) A situation in which the total supply of an approved (by the appropriate Health
Authority) drug is inadequate to meet the current or projected demand at the user
level.
EFPIA (European Federation of Pharmaceutical Industries and Associations, 2013) A potential drug shortage is defined as: the occurrence of internal or external
situations (single or in a combination of both), which result in an interruption of
supplies of a medicinal product, if not properly addressed and controlled.
Common position paper (Charnay-Sonnek et al., 2013) A situation in which the total supply of an authorized medicine or of a medicine used
on a compassionate basis is inadequate to meet the current or projected demand
at the patient level. The shortage may be local, national, European or international.
FIP (Fédération Internationale Pharmaceutique, 2013) A medicine shortage can be defined as a drug supply issue requiring a change. It
impacts patient care and requires the use of an alternative agent.
EAHC (Executive Agency for Health and Consumers, 2012) The availability to patients of medicinal products in a pharmacy setting.
ASHP (Fox et al., 2009) A supply issue that affects how the pharmacy prepares or dispenses a drug
product or influences patient care when prescribers must use an alternative agent.
Articles
Costelloe et al., 2014 A drug shortage was defined as the inability to purchase a particular drug from
wholesalers on a particular day.
Dragic, 2012 Drug shortage as every delay in monthly drug supply
Heiskanen et al., 2014 A drug supply issue requiring a change that impacts patient care and requires the
use of an alternative agent.
Pauwels et al., 2015 A shortcoming in the supply of a medicinal product that affects the patient’s ability
to access the required treatment in due time.
level (i.e., an order that is not delivered) are not considered as
drug shortages. As long as there is no demand for the drug
which is experiencing supply problems, these organizations do
not consider the situation as a drug shortage. The FDA, ISPE,
and the Australian Health Department complemented these
wordings with “at patient/user/consumer level” (Food and Drug
Administration, 2011b; Charnay-Sonnek et al., 2013; ISPE, 2013;
Australian Government - Department of Health - Therapeutic
Goods Administration [TGA], 2015). A small diﬀerence should
be acknowledged between “patient level” and “user or consumer
level.” The latter includes patients as well as healthy people using
the drug, e.g., in experiments.
Supply Side
Five deﬁnitions consider drug shortages at the level of
the supply side using expressions as “inadequate supply,”
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TABLE 2 | Overview of the reporting definitions of drug shortages.
Source Definition
National
ANSM (ANSM, 2014) Drugs for which unavailability cause a risk for public health and have no therapeutic
alternative.
AEMPS (Agencia Española de Medicamentos Y Productos Sanitarios - AEMPS,
2015)
All drugs which experience supply problems are reported, except for those for
which a rapid solution is expected.
BfArM (BfArM - Lieferengpässe, 2015) A supply shortage is expected to go beyond 2 weeks interruption extradition to the
usual extent or a significantly increased demand that cannot be adequately met.
Only supply shortages of drugs listed, where special information needs of
professionals are required. Currently, this is for prescription drugs that are intended
primarily for the treatment of life-threatening or serious diseases for which no
alternative preparations are available.
Belgian FAMHP (Federaal Agentschap voor Geneesmiddelen en
Gezondheidsproducten, 2014)
Holders of the market authorization should notify the Belgian FAMHP when a drug
will be unavailable for a time period longer than 14 days.
Farmanco (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie,
2014)
All supply problems of drugs are reported if it is expected that the drug will be
undeliverable for a time period longer than 14 days.
Canadian Drug Shortage Databank (Canadian Drug Shortage Database, 2015) As soon as a market authorization holder knows that it will take longer than 20 days
to supply a drug to meet expected patient volumes on an ongoing basis, they will
report this as a shortage on the communications platform. It is understood that the
inability of a patient to receive their prescribed medicines at the first attempt to fill a
prescription may not constitute a drug being in ‘shortage,’ as the drug may be
available in other pharmacies or within the wholesale or distribution network (i.e.,
pharmacy supply chain), usually within a few days.
Australian Medicine Shortages Information Initiative (Australian Government -
Department of Health - Therapeutic Goods Administration [TGA], 2015)
This information is based on the voluntary notification by sponsors in accordance
with the agreed Protocol.
European
EMA (European Medicines Agency, 2013) Medicines shortages that affect or are likely to affect more than one EU MS, where
the EMA has assessed the shortage and provided recommendations to patients
and healthcare professionals across the EU.
“interruption of supply,” or “supply issue.” Three out of the
ﬁve are general deﬁnitions, namely from the EFPIA, the Dutch
Institute for Rational Use of Medicines, and the FIP (see
Table 1) and additionally two reporting deﬁnitions: from the
BfArM and AEMPS (see Table 2; Instituut voor Verantwoord
Medicijngebruik, 2012; European Federation of Pharmaceutical
Industries and Associations, 2013; Fédération Internationale
Pharmaceutique, 2013; Agencia Española de Medicamentos Y
Productos Sanitarios - AEMPS, 2015; BfArM - Lieferengpässe,
2015). These expressions do not indicate by whom, pharmacy
or consumers, drug shortages should be perceived. Only the FIP
indicates in the sequel of the deﬁnition that this supply issue
impacts patient care (Fédération Internationale Pharmaceutique,
2013).
Delivery of a Drug
Deﬁnitions found in the Belgian and French laws, as well
as the deﬁnition formulated by the EMA in 2014, use the
phrase “undeliverable” as a basis for drug shortages (see
Table 1; Wet Betreﬀende de Verplichte Verzekering Voor
Geneeskundige Verzorging En Uitkeringen Gecoördineerd Op
14 Juli, 1994; Décret N◦ 2012-1096 Du 28 Septembre 2012 Relatif
À L’approvisionnement En Médicaments À Usage Humain,
2015). Again a diﬀerence is noticed regarding the speciﬁed level:
the Belgian law declares a situation as a drug shortage at the level
of community pharmacies, hospital pharmacies or wholesalers,
while the French law and EMA specify their deﬁnitions at
patient level (Wet Betreﬀende de Verplichte Verzekering Voor
Geneeskundige Verzorging En Uitkeringen Gecoördineerd Op
14 Juli, 1994; Décret N◦ 2012-1096 Du 28 Septembre 2012 Relatif
À L’approvisionnement En Médicaments À Usage Humain,
2015).
Availability of a Drug
The AIFA and the EAHCdeﬁne drug shortages as “the availability
of drugs to patients” (see Table 1; Executive Agency for Health
and Consumers, 2012; The Italien Medicines Agency, 2014). This
expression clariﬁes at which level drug shortages are considered,
however, it also regards access to medicines. The ANSM and
the FAMHP use the expression of “unavailable” to specify
the reporting conditions in France and Belgium (see Table 2;
ANSM, 2014; Federaal Agentschap voor Geneesmiddelen en
Gezondheidsproducten, 2014).
Considering the replies of the contacted organizations on the
question: “when do supply problems become drug shortages,”
diﬀerent opinions were observed. Answers are very divergent and
the following quotes highlight the diﬀerences between several
organizations on their approach to evaluating supply problems.
“All (supply) interruptions should be evaluated for their potential to
contribute to a shortage.” [R1]
“Supply problems should be considered as drug shortages when the
pharmacist or medical doctor has to change the prescription.” [R2]
“A supply problem becomes a shortage as soon as it has
consequences with regard to deliver medicines . . .” [R3]
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What about Permanent Discontinuation
of Drugs?
Drug shortages can be temporally (e.g., quality problems) or
permanent (e.g., withdrawal of the marketing authorization).
As discussed above, diverse wording formulations are found
to express drug shortages. Still it remains unclear for all
of these expressions whether they include temporally as
well as permanent discontinuation. After contacting diﬀerent
organizations, most organizations acknowledge the enormous
consequences of permanent cessation of drugs, but do not
consider it as a shortage, rather as an unavailability. The following
quotes illustrate the diﬀerent opinions:
“If a manufacturer decides to permanent discontinue a drug, there
are probably alternative treatments on the market” [R2]
“The deﬁnition can imply the permanent discontinuation of a drug,
because it means a shortage” [R3]
“The deﬁnition would include drugs that have been permanently
discontinued until medical and pharmacy practice change in
response to the discontinuation. Until prescribers stop prescribing
a speciﬁc drug product, pharmacists will still be addressing the lack
of availability, regardless of cause.” [R4]
Time Frame
Three general deﬁnitions, namely from the Belgian and the
French law and the Australian Health Department, incorporate
a period during which the drug is unavailable. Only two
of them indicate an exact time frame, both references are
provided by national laws. The Belgian law declares “an
uninterrupted period of four days” as time frame, while
the French law deﬁnes drug shortages as situations where
drugs are “undeliverable for three days” (Wet Betreﬀende de
Verplichte Verzekering Voor Geneeskundige Verzorging En
Uitkeringen Gecoördineerd Op 14 Juli, 1994; Décret N◦ 2012-
1096 Du 28 Septembre 2012 Relatif À L’approvisionnement
En Médicaments À Usage Humain, 2015). The Australian
Health Department uses an undeﬁned timeframe noting “not
likely to meet the demand for a period of time” (Australian
Government - Department of Health - Therapeutic Goods
Administration [TGA], 2015). It remains unclear when the
Australian government will consider supply problems as a
shortage; this period can range from one day to one month or
even longer.
Most organizations agree that a time frame in a deﬁnition is
superﬂuous, since it occurs that for instance in the northern part
of a country a shortage is experienced while in the southern part
the drug is still available.
“In terms of a deﬁnition, then a time scale would seem to have little
relevance.” [R1]
“. . . as soon as a pharmacist cannot deliver a prescription drug . . .
there is a shortage.” [R3]
On the other hand, a speciﬁed time frame is often (in
four of the eight deﬁnitions) used as a condition to report
drug shortages (Federaal Agentschap voor Geneesmiddelen
en Gezondheidsproducten, 2014; Government of Canada -
Health Canada, 2014; Koninklijke Nederlandse Maatschappij
ter bevordering der Pharmacie, 2014; BfArM - Lieferengpässe,
2015). Three databases will report shortages that go beyond
14 days, namely the FAMHP, Farmanco, and BfArM (Federaal
Agentschap voor Geneesmiddelen en Gezondheidsproducten,
2014; Koninklijke Nederlandse Maatschappij ter bevordering der
Pharmacie, 2014; BfArM - Lieferengpässe, 2015). The Canadian
drug shortages database reports only drug shortages which will
take longer than 20 days (Government of Canada - Health
Canada, 2014). AEMPS uses an undeﬁned time frame; they will
report all shortages unless a rapid solution is expected (Agencia
Española de Medicamentos Y Productos Sanitarios - AEMPS,
2015).
Typology
Including a time frame is one way to decrease the workload
of (inter)national authorities when reporting drug shortages.
Another way to decrease the workload of reporting drug
shortages is by making a typology of the aﬀected disease
classes. This approach is only observed in reporting deﬁnitions
and thus should be considered as a condition to report
shortages. Databases of Germany and France will only report
drugs which are intended for the treatment of life-threatening
or serious diseases for which no alternative preparations are
available (ANSM, 2014; BfArM - Lieferengpässe, 2015). In Spain,
Belgium, the Netherlands and Canada no explicit typology
is included in the deﬁnition and thus all drugs experiencing
supply problems will be reported (Federaal Agentschap voor
Geneesmiddelen en Gezondheidsproducten, 2014; Koninklijke
Nederlandse Maatschappij ter bevordering der Pharmacie, 2014;
Government of Canada - Health Canada, 2014; Agencia
Española de Medicamentos Y Productos Sanitarios - AEMPS,
2015).
DISCUSSION
This study provides an overview of 26 unique deﬁnitions for
drug shortages as provided by two legislations, ﬁve governmental
organizations, seven professional organizations, four from
scientiﬁc articles, seven national reporting databases and
one European reporting database (see Tables 1 and 2; Wet
Betreﬀende de Verplichte Verzekering Voor Geneeskundige
Verzorging En Uitkeringen Gecoördineerd Op 14 Juli, 1994; Fox
et al., 2009; Food and Drug Administration, 2011b; Dragic, 2012;
Executive Agency for Health and Consumers, 2012; Instituut
voor Verantwoord Medicijngebruik, 2012; Charnay-Sonnek
et al., 2013; European Medicines Agency, 2013; European
Federation of Pharmaceutical Industries and Associations, 2013;
Fédération Internationale Pharmaceutique, 2013; ANSM, 2014;
Costelloe et al., 2014; Federaal Agentschap voor Geneesmiddelen
en Gezondheidsproducten, 2014; Government of Canada -
Health Canada, 2014; Heiskanen et al., 2014; ISPE, 2014;
The Italien Medicines Agency, 2014; Agencia Española
de Medicamentos Y Productos Sanitarios - AEMPS, 2015;
Australian Government - Department of Health - Therapeutic
Goods Administration [TGA], 2015; BfArM - Lieferengpässe,
2015; Canadian Drug Shortage Database, 2015; Décret N◦
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2012-1096 Du 28 Septembre 2012 Relatif À L’approvisionnement
En Médicaments À Usage Humain, 2015; Pauwels et al.,
2015). A summary of the diﬀerent elements in deﬁnitions
is presented, accompanied by the conditions which are
currently used to report drug shortages. The diﬀerences and
similarities were compared and quotation marks with underlying
reasons for a better understanding of the deﬁnitions were
added.
Currently two types of deﬁnitions are in circulation: general
deﬁnitions to designate a drug shortage and reporting deﬁnitions
to specify when to report a drug shortage. This distinction
is also implemented in the results section due to essential
diﬀerences between the two types of deﬁnitions. However, in
the future, one should aim at aggregating both deﬁnitions into
one to facilitate the comparison of reporting databases and
scientiﬁc studies. A general deﬁnition should be developed to
designate a drug shortage and additionally one must specify
uniform conditions to report shortages. The general deﬁnition
together with its reporting conditions should be developed
in consultation with all stakeholders which are confronted
with drug shortages and should be addressed to all diﬀerent
stakeholders. EU policy makers are best placed to set up a
stakeholder forum where the main elements of the general
deﬁnition together with its reporting deﬁnition can be discussed.
We propose to include the deﬁnition and the reporting
conditions in an EU Directive to reach more harmonized
reporting databases based on the same deﬁnition, leaving the
national authorities the responsibility on the means to achieve
this goal.
To deﬁne this uniform deﬁnition for drug shortages, diﬀerent
decisions should be made. In the ﬁrst place, one must determine
which expression will be used to describe a drug shortage
and at which level a drug shortage should be considered. At
this moment four expressions are found: (i) when the supply
cannot meet the demand, (ii) in case of an interruption of
supply, (iii) when the drug is undeliverable, or (iv) when
the drug is unavailable. Afterward the level of drug shortages
should be determined. “At patient level” seems harder to
identify in practice, while “an undelivered order” appears
easier to detect. If the prices of drugs would be subjected
to “free market” principles (i.e., a system in which prices for
goods are set freely between vendors and consumers) a drug
shortage, from an economic point of view, should be deﬁned
according to the demand side, because a shortage can only
occur when the demand exceeds the supply (Simoens et al.,
2005).
Whether to include permanent discontinuations is a
third issue to be considered. Permanent discontinuations
are subject to other rules in case of reporting the problem,
therefore it might be easier to set proper conditions for
temporary shortages and permanent ones (De Weerdt
et al., 2015). Still it remains important to inform patients
properly when a drug will be withdrawn from the
market.
Incorporating a time frame in the general deﬁnition seems
rather irrelevant for the following two reasons. First, only
legislations contain time frames in their deﬁnitions. This can
be explained by the necessity for the practical implementation
of the legislations. Secondly, every country has its own policy
on the delivery of drugs therefore it might be hard to come
to one time frame which can be generally applied. However,
including a time frame as a reporting condition should be
considered a feasible method to reduce the workload of
the competent authority, especially since four of the eight
references already included a speciﬁed time frame (Federaal
Agentschap voor Geneesmiddelen en Gezondheidsproducten,
2014; Koninklijke Nederlandse Maatschappij ter bevordering
der Pharmacie, 2014; BfArM - Lieferengpässe, 2015; Canadian
Drug Shortage Database, 2015). The three European references
(Germany, The Netherlands, and Belgium) speciﬁed that a
drug should be in shortage for at least 14 days (Federaal
Agentschap voor Geneesmiddelen en Gezondheidsproducten,
2014; Koninklijke Nederlandse Maatschappij ter bevordering der
Pharmacie, 2014; BfArM - Lieferengpässe, 2015), and perhaps
this can be extended to all EU Member States’ databases.
Reducing the workload of competent authorities who are
responsible for the drug shortages database can also be
obtained by only including “drugs shortages which cause
a risk for public health”. This is observed in Germany
and France (ANSM, 2014; BfArM - Lieferengpässe, 2015).
However, these restrictions will also misrepresent the size of
the problem because not all shortages will be covered by the
databases.
Diﬀerences between the found deﬁnitions of drug shortages
can be partly explained by the diversity of stakeholders.
Deﬁnitions in national legislations have other purposes than
the deﬁnitions of drug shortages of professional organizations.
This can be explained by the diﬀerent roles, responsibilities
and expectations of the diﬀerent stakeholders. E.g. a time
frame is found in national laws and not in deﬁnitions of
professional organizations, probably because national legislations
consider the speciﬁcities of the local drug market. However, this
does not explain the diﬀerences within a group of the same
stakeholders, which may be attributed to the diﬀerent missions
of the organizations. E.g., the deﬁnition of the EFPIA is very
broad and will encounter a lot more drug shortages compared
to the deﬁnition of the FIP. Although the diﬀerences between
and within stakeholders, the fact that so many organizations
are troubled with this problem and searching for solutions,
harmonization on the deﬁnition of drug shortages at EU level
seems possible.
A diﬀerence should be noted in the terms “drug shortage”
and “drug unavailability”. A drug shortage is deﬁned as
“an interruption of supply chain”, while drug unavailability
rather refers to “not introducing new, innovative drugs to
the market” (De Weerdt et al., 2015). However, the Belgian
federal agency denotes to unavailability instead of shortage and
should be willing to reformulate its deﬁnitions in order to avoid
confusion.
Obtaining a uniform deﬁnition for drug shortages is
important as well as identifying which conditions are preferable
to report drug shortages in order to facilitate international
comparison. This paper can be used as a guidance to point out all
the diﬀerent elements which should be considered to formulate a
Frontiers in Pharmacology | www.frontiersin.org 7 October 2015 | Volume 6 | Article 253
De Weerdt et al. How should drug shortages be defined?
uniform deﬁnition applied in the EU. Nevertheless, the deﬁnition
should acknowledge diﬀerent national legislations and opinions
of diverse stakeholders. The only way to obtain this is to sit
around the table with all stakeholders involved with supply
problems, which should be the next step in this investigation.
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